KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Current Liabilities (2017 - 2025)

Aquestive Therapeutics has reported Total Current Liabilities over the past 9 years, most recently at $47.6 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $47.6 million for Q4 2025, up 152.36% from a year ago — trailing twelve months through Dec 2025 was $47.6 million (up 152.36% YoY), and the annual figure for FY2025 was $47.6 million, up 152.36%.
  • Total Current Liabilities for Q4 2025 was $47.6 million at Aquestive Therapeutics, up from $25.6 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for AQST hit a ceiling of $47.6 million in Q4 2025 and a floor of $13.9 million in Q2 2024.
  • Median Total Current Liabilities over the past 5 years was $23.6 million (2023), compared with a mean of $26.1 million.
  • Biggest five-year swings in Total Current Liabilities: plummeted 64.05% in 2024 and later soared 152.36% in 2025.
  • Aquestive Therapeutics' Total Current Liabilities stood at $22.0 million in 2021, then surged by 79.97% to $39.5 million in 2022, then plummeted by 53.68% to $18.3 million in 2023, then rose by 3.04% to $18.9 million in 2024, then soared by 152.36% to $47.6 million in 2025.
  • The last three reported values for Total Current Liabilities were $47.6 million (Q4 2025), $25.6 million (Q3 2025), and $23.2 million (Q2 2025) per Business Quant data.